Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis-Reference-Cited by-同舟云学术

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Published:2022-03 Issue:3 Volume:164 Page:498-504
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Poveda A.,Lheureux S.,Colombo N.,Cibula D.,Lindemann K.,Weberpals J.,Bjurberg M.,Oaknin A.,Sikorska M.,González-Martín A.,Madry R.,Pérez M.J. Rubio,Ledermann J.,Davidson R.,Blakeley C.,Bennett J.,Barnicle A.,Škof E.

Funder

Merck & Co Inc

Merck Sharp and Dohme

AstraZeneca PLC

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference28 articles.

1. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status;Gadducci;J Ovarian Res.,2019

2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature.,2005

3. Targeting the DNA damage response in cancer;O'Connor;Mol. Cell,2015